Renée Aguiar-Lucander

Renée Aguiar-Lucander

Chief Executive Officer at HANSA BIOPHARMA AB

Net worth: 989 439 $ as of 2026-10-30

64 year
Health Technology
Commercial Services
Finance

Profile

Renée Julie Elisabet Aguiar-Lucander is currently Chief Executive Officer at Hansa Biopharma AB since 2025.
Also holds Chairman positions at Simparel, Inc. and Exenta, Inc. Serves as Director at Inventiva SA since 2025, AC Immune SA as Independent Director since 2025, Egalet A, and Ral Capital Ltd. (United Kingdom).
Formerly Chief Executive Officer at Calliditas Therapeutics AB from 2017 to 2025.
Previously Chairman at EnXray Ltd. and Director at SpineVision SAS, ImpactRx, Inc., Zyla Life Sciences LLC (Independent Director), Pulmagen Therapeutics (Synergy) Ltd. (Non-Executive Director), MedCap AB (Independent Director), Newron Pharmaceuticals SpA (Independent Non-Executive Director, 2006–2011), SciBase Holding AB (Independent Director), NsGene A, Egalet Ltd. (Independent Director, 2013), Onyvax Ltd., Lehman Brothers, Inc. (Milan Branch) as Managing Director-Corporate Finance in 2003, Sophion Bioscience A, BioSilta Ltd., Danish BioVenture General Partner ApS, Calliditas Therapeutics France SAS, 3i Group Plc (Partner), 3i Venture Capital (Partner), and Omega Fund Management UK LLP as Chief Operating Officer & Partner.
Education includes an MBA from INSEAD and undergraduate studies at Stockholm School of Economics.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-09-24 197,000 ( 0.19% ) 788 236 $ 2026-10-30
2026-06-10 51,136 ( 0.05% ) 113 522 $ 2026-10-30
2026-02-28 24,700 ( 0.01% ) 87 681 $ 2026-10-30

Renée Aguiar-Lucander active positions

CompaniesPositionStart
HANSA BIOPHARMA AB Chief Executive Officer 2025-04-23
INVENTIVA Director/Board Member 2025-05-21
AC IMMUNE SA Director/Board Member 2025-06-18
Chairman -
Chairman -
Director/Board Member -
Ral Capital Ltd. (United Kingdom)
Director/Board Member -

Former positions of Renée Aguiar-Lucander

CompaniesPositionEnd
CALLIDITAS THERAPEUTICS AB Chief Executive Officer 2024-12-31
ZYLA LIFE SCIENCES Director/Board Member 2015-06-09
░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
See the detail of Renée Aguiar-Lucander's experience

Education of Renée Aguiar-Lucander

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

65

1st degree connections

29

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies29

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Omega Fund Management UK LLP

Finance

Health Technology

Health Technology

Technology Services

Commercial Services

Technology Services

Ral Capital Ltd. (United Kingdom)

  1. Stock Market
  2. Insiders
  3. Renée Aguiar-Lucander